Skip to main content

Table 1 Summary of the design and structure of clinically tested bioresorbable scaffolds

From: Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention

Scaffold Strut material Coating material Eluted drug Strut thickness (μm) Resorption (month) Current status
Igaki-Tamai PLLA None None 170 24–36 CE mark for peripheral use
AMS-1 Mg None None 165 <4 Discontinued
DREAMS-1 Mg PLGA Paclitaxel 125 9 Clinical trials
DREAMS-2 Mg PLLA Sirolimus 150 9 Clinical trials
Absorb BVS 1.0 PLLA PDLLA Everolimus 156 18–24 Discontinued
Absorb BVS 1.1 PLLA PDLLA Everolimus 156 24–48 CE mark
Absorb BVS-New generation PLLA PDLLA Everolimus <100 NA NA
DeSolve PLLA None Myolimus 150 12–24 CE mark
DeSolve 100 PLLA PLLA Novolimus 100 24 CE mark
IDEAL biostent Polymer salicylate Salicylate Sirolimus 175 >12 Clinical trials
REVA PTD-PC None None 200 24 Discontinued
ReZolve PTD-PC None Sirolimus 115–230 4–6 Clinical trials
ReZolve2 PTD-PC None Sirolimus 100 48 Clinical trials
Fantom PTD-PC - Sirolimus 125 36 Clinical trials
Fortitude semicrystalline polylactide - None 150–200 3–6 Clinical trials
Mirage BRMS PLLA - Sirolimus 125–150 14 Clinical trials
MeRes PLLA PDLLA Sirolimus 100 24 Clinical trials
Xinsorb PLLA PDLLA Sirolimus 160 24–36 Clinical trial
ART 18AZ PDLLA None None 170 3–6 Clinical trials
  1. Mg magnesium, PLLA poly-L-lactic acid, PDLLA poly-DL-lactic acid, BVS bioresorbable vascular scaffold
  2. SA/AA salicylic acid/adipic acid, PTD-PC, poly-tyrosine-derived polycarbonate, CE Conformité
  3. Européenne. NA not available